Amgen Inc.

Other

Eli Lilly and Company

University of South Florida

Wayne State University

University of Hawai'i

Genzyme Corporation

Vinod Francis Patel

Joseph L Kim

Michael D Croghan

Matthew M Weiss

Stephanie Geuns-Meyer

Patricia Lopez

Wenge Zhong

Yuan Cheng

Julie Germain

Ning Xi

Daniel La

Tae-Seong Kim

Charles Kreiman

Daniel Elbaum

Qiufen May Xue

Russell Graceffa

Andrew Stewart Tasker

Stephen A Hitchcock

Holger Monenschein

Thomas T Nguyen

Brian Lewis Hodous

Shon Booker

Ted Charles Judd

Chester Chenguang Yuan

Lucian V DiPietro

Bryant Yang

Craig E Masse

Brian K Albrecht

Matthew R Kaller

Shimin Xu

Scott S Harried

Qi Huang

Guoqing Paul Chen

Celia Dominguez

Jean E Bemis

James A Brown

Lewis D Pennington

Thomas Dineen

Steven F Bellon

Michael D Bartberger

Hanh Nho Nguyen

Joseph J Nunes

Thomas Nixey

Randall W Hungate

Jean-Christophe P Harmange

Leon M Smith, Ii

Ryan D White

Victor J Cee

Daniel B Horne

Karina Romero

Matthew W Martin

Nobuko Nishimura

Xiaotian Zhu

Bryan Hurst Norman

Guolin Cai

Aiwen Li

Paul A Tempest

Jason Brooks Human

David Craig McGowan

Qingyian Liu

David M Armistead

Albert Kudzovi Amegadzie

Vu Van Ma

Alan C Cheng

Isaac E Marx

Wenyuan Qian

Markian Myroslaw Stec

Perry M Novak

Rosanne Bonjouklian

Benny C Askew

Erin F DiMauro

Deborah Choquette

Gang Liu

Jian Jeffrey Chen

Michael J Martinelli

Anthony B Reed

Robert Michael Rzasa

Longbin Liu

Chuan Shih

Kevin Chao Yang

Ho-Shen Lin

Brian Stephen Muehl

Liping H Pettus

John E Munroe

Ana Elena Minatti

Michael Enrico Richett

Dawei Zhang

Kenneth Jeff Thrasher

Louis Nickolaus Jungheim

Angel Guzman-Perez

Laurie B Schenkel

John E Toth

James Richard Falsey

Jeremy Schulenburg York

Richard E Moore

James E Ray

Hakan Gunaydin

John L Kane, Jr

Julian Stanley Kroin

Adrian Leonard Smith

Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Colony stimulating factor-1 receptor (CSF-1R) inhibitors

A cardiopulmonary resuscitation (CPR) device for performing automatic defibrillation and chest compressions on a patient and method for using same. The CPR device having a balloon configured to inflate/deflate, a belt configured to securely strap around a chest of a patient, a pair of electrode pads configured to deliver shock energy from a shock source, and, optionally, a pulse oximeter sensor. The CPR device is in electrical communication with a CPR defibrillator/ECG computer system that is configured to control the CPR device.

Method and apparatus for treatment of cardiopulmonary arrest

A method and device for the treatment of hypertrophic cardiomyopathy. The device includes a cutting device for resection of a thickened myocardium. The operator positions the cutting device adjacent to the myocardium that is to be resected and then slides a tubular blade within an outer shell of the cutting device to resect the septum.

Device for the treatment of hypertrophic cardiomyopathy

An umbrella has a lower pole and an upper pole and a fabric. The lower pole includes screw threads. A spring clip in an inverted V-shaped configuration has outwardly extending projections removably coupling together the upper pole and the lower pole. A handle is removably coupled to the lower pole to twist the lower pole. Each rib of a plurality of ribs has an interior end and an exterior end. The interior ends of the ribs are coupled to the upper pole. The fabric overlies the ribs. Each tip of a plurality of tips has an upper part and a lower part. Each upper part has a tubular recess receiving the exterior end of an associated rib. The periphery of the fabric is secured between the upper part and the lower part.

Beach umbrella system

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I); wherein variables A, A, A, A, A, A, R, R, X and Y of Formula (I) are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and sub-formula embodiments of Formula (I) and (II), intermediates and processes and methods useful for the preparation of compounds of Formulas (I)-(II). 

5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use

Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein. 

Oxazolidinone compounds and derivatives thereof

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, A, A, A, A, R, R, X, Y and Z of Formula I are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to plaque formation and deposition, resulting from the activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits and impairments, schizophrenia and other central nervous system conditions and disorders. The invention further provides compounds of Formulas II and III, and of sub-formulas of Formulas I, II and III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use

Method and device for the treatment of hypertrophic cardiomyopathy

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A, A, A, A, A, A, R, R, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use

The present invention relates to compounds of Formulas I and II, wherein B, B, B, B, C, C, ring D, L, Land Rare defined herein, synthetic intermediates, and pharmaceutical compositions, comprising such compounds. The compounds and compositions are capable of modulating various protein kinase receptors such as Tie-2 and Aurora and, therefore, influencing kinase related disease states and conditions. The compounds, for example, are capable of treating cancer caused by unregulated angiogenesis, and inflammation as well as other proliferative disorders.

Multi-cyclic compounds and methods of use

Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

Substituted alkylamine derivatives and methods of use

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase activity and for the treatment of diseases, including Alzheimer's disease (AD) and related CNS conditions, mediated thereby. In one embodiment, the compounds have a general Formula I or Formula II wherein R, B, Rand W of Formula I, and R, R, A, W, X, Z, m and n of Formula II are defined herein. The invention further provides compounds of Formula III and IV and sub-Formulas II-A-II-D and III-A-III-D. The compounds may be used in pharmaceutical compositions for treating, prophylactically or therapeutically, disorders related to the activity of beta-secretase protein, including without limitation, AD, cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions.

Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use

The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, Hand Rare defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.

Protein kinase modulators and method of use

The umbrella includes a shaft, a lower canopy having a central opening, and an upper canopy thereabove over the opening. A first supporting assembly includes ribs, stretchers, and a runner and is connected to the shaft and first and second canopies to operably move the canopies between closed and open positions, wherein an inner portion of the upper canopy moves with the ribs. A second supporting assembly is connected to the ribs of the first assembly within the opening and connected to an outer portion of the upper canopy for operably moving the outer portion of the upper canopy between concave and convex positions while the lower canopy and inner portion of the upper canopy are retained in the concave position, such that the outer portion of the upper canopy covers the opening when concave to restrict air passage and exposes the opening when convex to permit air passage.

Umbrella with multiple canopy structure

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, A, A, A, A, A, T, T, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use

Growing community of inventors

Waltham, MA, United States of America

Vinod Francis Patel